Urology · Enid, OK
NPI
1336141696
Since 2005
Specialty
Urology
Code 208800000X
Group practices
1
Medicare group memberships
Hospitals
5
Hospital affiliations
615 E. Oklahoma Ave., Ste 202
Enid, OK, 73701
Phone (580) 233-3230
Groups this clinician bills Medicare through
Medicare paid, 2024
$412K
17,901 services
Medicare patients, 2024
1,206
Average age 77
Drug cost, 2024
$727K
3,019 prescriptions
Company payments, 2025
$467
From 14 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Rodney L Worthen II was code Q9967 (low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml), 7,768 times for 84 patients. In total Rodney L Worthen II billed 17,901 services in 97 codes, and Medicare paid $412K.
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2014-08-26.
| Code | Setting | Services | Patients | Paid per service | Medicare paid |
|---|
| Q9967 Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | Office | 7,768 | 84 | $0.11 | $825 |
| 99214 Office E&M - Established | Office | 2,083 | 1,059 | $83.77 | $174K |
| J9030 Bcg live intravesical instillation, 1 mg | Office | 2,068 | 13 | $2.27 | $4,689 |
| 81003 Clinical Chemistry | Office | 1,479 | 791 | $2.19 | $3,244 |
| 51798 Ultrasound - Nonspecific | Office | 1,013 | 687 | $7.05 | $7,139 |
| G2211 Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | Office | 739 | 532 | $11.62 | $8,584 |
| J9217 Leuprolide acetate (for depot suspension), 7.5 mg | Office | 254 | 40 | $138.64 | $35K |
| 99204 Office E&M - New | Office | 179 | 179 | $112.14 | $20K |
| 52000 Cystourethroscopy | Office | 168 | 143 | $148.86 | $25K |
| 99213 Office E&M - Established | Office | 153 | 105 | $59.69 | $9,133 |
| 74176 CT/CTA - Abdomen and Pelvis | Office | 93 | 64 | $69.87 | $6,498 |
| 51741 Test - Miscellaneous | Office | 86 | 73 | $5.61 | $482 |
| 51720 Chemotherapy Administration | Office | 84 | 18 | $61.48 | $5,164 |
| 96402 Chemotherapy Administration | Office | 83 | 40 | $22.65 | $1,880 |
| 51702 Other Organ Systems | Office | 76 | 17 | $42.17 | $3,205 |
By year: 2022 $312K for 14,596 services; 2023 $312K for 12,719 services; 2024 $412K for 17,901 services.
Lab tests billed to Medicare, 2024
| Test code | Tests | Patients | Paid per test | Medicare paid |
|---|---|---|---|---|
| 81003 Clinical Chemistry | 1,479 | 791 | $2.19 | $3,244 |
Medicare prescription drug claims, 2024
In 2024, the drug Rodney L Worthen II prescribed most often to Medicare patients was Tamsulosin Hcl, with 623 prescriptions and refills. In total Rodney L Worthen II wrote 3,019 Medicare prescriptions that cost $727K.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Tamsulosin Hcl Generic | 623 | 1,625 | 197 | $10K |
| Dutasteride Generic | 324 | 768 | 88 | $9,801 |
| Finasteride Generic | 299 | 752 | 83 | $5,210 |
| Alfuzosin Hcl Er Alfuzosin Hcl | 253 | 595 | 71 | $6,156 |
| Bethanechol Chloride Generic | 224 | 424 | 58 | $18K |
| Methenamine Hippurate Generic | 168 | 306 | 38 | $8,719 |
| Cephalexin Generic | 158 | 158 | 110 | $1,330 |
| Ciprofloxacin Hcl Generic | 130 | 130 | 100 | $648 |
| Myrbetriq Mirabegron | 65 | 87 | 12 | $36K |
| Gemtesa Vibegron | 57 | 67 | 11 | $31K |
| Doxycycline Monohydrate Generic | 52 | 52 | 47 | $941 |
| Meloxicam Generic | 44 | 44 | 37 | $144 |
| Xtandi Enzalutamide | 41 | 41 | Under 11 | $576K |
| Oxybutynin Chloride Er Oxybutynin Chloride | 41 | 89 | 14 | $394 |
| Tolterodine Tartrate Er Tolterodine Tartrate | 38 | 48 | 18 | $1,256 |
Brand drugs: 199 claims; generic drugs: 2,820 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Rodney L Worthen II $467 ($467 in general payments such as food, travel and fees) from 14 companies. The largest payer was Ferring Pharmaceuticals Inc. with $66.79.
| Company | Payments | Amount |
|---|---|---|
| Ferring Pharmaceuticals Inc. | 4 | $66.79 |
| Teleflex LLC TFX | 2 | $48.76 |
| Astellas Pharma US Inc 4503.T | 2 | $43.66 |
| Procept Biorobotics Corporation PRCT | 1 | $39.94 |
| Pfizer Inc. PFE | 2 | $38.17 |
| Abbvie Inc. ABBV | 2 | $35.76 |
| Bayer Healthcare Pharmaceuticals Inc. BAYN.DE | 2 | $33.76 |
| Sumitomo Pharma America, Inc. 4506.T | 2 | $33.76 |
| Coloplast Corp | 2 | $32.91 |
| Medtronic, Inc. MDT | 1 | $22.6 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.